Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Bempedoinsäure + Ezetimib, (OBO) ATC C10BA10 für die Zeit 01.03.2025 - 28.02.2027

Health · Germany government procurement

Closed December 29, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient bempedoic acid + ezetimibe, (OBO) ATC C10BA10 for the period 01.03.2025 - 28.02.2027

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedJanuary 16, 2025
Procurement stageActive solicitation
ClosedDecember 29, 2026
StatusClosed — no longer accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Browse Similar Open Opportunities in Germany

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Xipamid, ATC C03BA10
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV88
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin zeta, ATC B03AX01
Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) by way of an open-house model for the active ingredient tamsulosin/dutasteride (WHO ATC code: G04CA52)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Baumpollen, ATC V01AA05
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Formoterol, Glycopyrroniumbromid und Budesonid , ATC R03AL11
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Omalizumab (ATC: R03DX05)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Colecalciferol, non RX, ausschließlich nach Anlage 1 AM-RL G-BA verordnungsfähige Produkte, ATC A11CC05

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.